We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 19.00 | 1.07% | 1,799.50 | 1,796.00 | 1,796.50 | 1,799.50 | 1,780.00 | 1,784.00 | 9,804,173 | 16:35:21 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 15.00 | 73.94B |
From May 2019 to May 2024
TIDMGSK
RNS Number : 4291X
GlaxoSmithKline PLC
05 May 2016
GlaxoSmithKline plc
Result of AGM
GlaxoSmithKline plc ('GSK') announces that at its Annual General Meeting ('AGM') today, all resolutions were passed by shareholders. The full text of each resolution is contained in the 2016 Notice of AGM, which is available on the GSK website, www.gsk.com.
GSK AGM Poll Results
The following table shows the total number of votes cast for each resolution:
Hot Features
Premium
Resolution Total % Total % Total Votes
votes votes votes withheld(**)
for(*) against cast
--------------------- -------------- ------ ------------ ------ -------------- --------------
To receive
the 2015
Annual
1 Report 3,669,218,924 99.05 35,061,988 0.95 3,704,280,912 5,261,084
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Approval
of the
Annual
Remuneration
2 Report 2,540,987,583 84.66 460,527,692 15.34 3,001,515,275 708,024,810
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Election
of Vindi
3 Banga 3,685,603,989 99.46 20,087,621 0.54 3,705,691,610 3,847,903
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Election
of Dr Jesse
4 Goodman 3,700,820,176 99.86 5,098,265 0.14 3,705,918,441 3,621,220
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Re-election
of Sir
Philip
5 Hampton 3,678,982,107 99.28 26,862,132 0.72 3,705,844,239 3,698,027
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Re-election
of Sir
Andrew
6 Witty 3,683,792,948 99.40 22,182,401 0.60 3,705,975,349 3,569,171
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Re-election
of Professor
Sir Roy
7 Anderson 3,613,878,165 97.52 92,011,809 2.48 3,705,889,974 3,648,285
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Re-election
of Stacey
8 Cartwright 3,614,959,774 97.55 90,964,624 2.45 3,705,924,398 3,615,316
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Re-election
of Simon
9 Dingemans 3,546,542,373 95.70 159,260,080 4.30 3,705,802,453 3,739,812
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Re-election
of Lynn
10 Elsenhans 3,689,867,659 99.57 16,065,159 0.43 3,705,932,818 3,606,897
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Re-election
of Judy
11 Lewent 3,603,842,229 97.24 102,181,719 2.76 3,706,023,948 3,513,813
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Re-election
of Urs
12 Rohner 3,592,628,299 96.95 113,209,089 3.05 3,705,837,388 3,695,508
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Re-election
of Dr Moncef
13 Slaoui 3,600,056,654 97.14 105,875,118 2.86 3,705,931,772 3,611,731
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Re-appointment
14 of auditors 3,641,870,505 98.24 65,155,953 1.76 3,707,026,458 2,515,807
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Remuneration
15 of auditors 3,693,883,936 99.68 12,020,539 0.32 3,705,904,475 3,632,301
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Authority
for the
company
to make
donations
to political
organisations
and incur
political
16 expenditure 3,614,540,404 98.19 66,705,675 1.81 3,681,246,079 28,294,561
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Authority
to allot
17 shares 3,557,940,858 96.09 144,791,595 3.91 3,702,732,453 6,808,690
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Disapplication
of pre-emption
18 rights(***) 3,206,747,187 88.23 427,795,940 11.77 3,634,543,127 74,993,676
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Authority
for the
company
to purchase
its own
19 shares(***) 3,591,814,300 96.93 113,781,713 3.07 3,705,596,013 3,952,127
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Exemption
from statement
of senior
statutory
auditor's
20 name 3,648,560,466 99.15 31,169,134 0.85 3,679,729,600 29,811,350
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Authorise
reduced
notice
of a general
meeting
other than
21 an AGM(***) 3,223,721,215 87.61 455,747,014 12.39 3,679,468,229 30,073,919
--- ---------------- -------------- ------ ------------ ------ -------------- --------------
Notes:
* Includes discretionary votes.
** A vote withheld is not a vote in law and is not counted in the calculation of the proportion
of votes "For" or "Against" a resolution.
*** Indicates Special Resolutions requiring a 75% majority.
The Board notes the votes against and withheld in respect of resolution 2, the approval of the Remuneration Report. The Remuneration Committee will be conducting a review of the Directors' Remuneration Policy during 2016 and will consult and engage with major investors in advance of the vote on the Company's Remuneration Policy Report at our 2017 AGM.
Dr Stephanie Burns, Sir Deryck Maughan, Dr Daniel Podolsky and Hans Wijers did not stand for re-election as Directors, and stepped down from the Board with effect from the conclusion of the AGM.
In accordance with section 430(2B) of the Companies Act 2006, GSK confirms that Dr Stephanie Burns, Sir Deryck Maughan, Dr Daniel Podolsky and Hans Wijers will receive payment of fees for service whilst a Director but no other remuneration payment or payment for loss of office will be made in connection with their departure.
The following table provides further relevant information:
GSK's Sixteenth GSK's
AGM Fifteenth AGM
(2016) (2015)
--------------------------------- ------------------ ----------------
Issued share capital (excluding
Treasury Shares) 4,871,555,095 4,866,216,110
--------------------------------- ------------------ ----------------
Total votes cast and votes
withheld lodged as a % of
GSK's issued share capital
(excluding Treasury Shares) 76.15% 75.30%
--------------------------------- ------------------ ----------------
Total shareholder population 132,895 137,658
--------------------------------- ------------------ ----------------
Total number of proxies
lodged 8,020 8,686
--------------------------------- ------------------ ----------------
% of shareholders who lodged
proxies 6.03% 6.31%
--------------------------------- ------------------ ----------------
Number of shareholders,
corporate representatives
and proxies who attended
the AGM 448 403
--------------------------------- ------------------ ----------------
V A Whyte
Company Secretary
5 May 2016
These results will shortly be available on the company's website at www.gsk.com.
GSK enquiries:
UK Media enquiries: David Mawdsley +44 (0) 20 (London)
8047 5502
Simon Steel +44 (0) 20 (London)
8047 5502
Eleanor Craven +44 (0) 20 (London)
8047 5502
Anna Carruth +44 (0) 20 (London)
8047 5502
US Media enquiries: Sarah Alspach +1 202 715 (Washington,
1048 DC)
Sarah Spencer +1 215 751 (Philadelphia)
3335
Jenni Ligday +1 202 715 (Washington,
1049 DC)
Analyst/Investor Ziba Shamsi +44 (0) 20 (London)
enquiries: 8047 5543
Tom Curry + 1 215 751 (Philadelphia)
5419
Gary Davies +44 (0) 20 (London)
(MORE TO FOLLOW) Dow Jones Newswires
May 05, 2016 12:41 ET (16:41 GMT)
8047 5503
James Dodwell +44 (0) 20 (London)
8047 2406
Jeff McLaughlin +1 215 751 (Philadelphia)
7002
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGAKPDNABKDCPK
(END) Dow Jones Newswires
May 05, 2016 12:41 ET (16:41 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
